396 related articles for article (PubMed ID: 24771277)
1. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.
Hundemer M; Engelhardt M; Bruckner T; Kraeker S; Schmitt A; Sauer S; Neben K; Witzens-Harig M; Goldschmidt H; Ho AD; Wuchter P
J Clin Apher; 2014 Dec; 29(6):299-304. PubMed ID: 24771277
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
3. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
4. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients.
Varmavuo V; Mäntymaa P; Silvennoinen R; Nousiainen T; Kuittinen T; Jantunen E
Transfusion; 2013 May; 53(5):1024-32. PubMed ID: 22897584
[TBL] [Abstract][Full Text] [Related]
5. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
Shaughnessy P; Islas-Ohlmayer M; Murphy J; Hougham M; MacPherson J; Winkler K; Silva M; Steinberg M; Matous J; Selvey S; Maris M; McSweeney PA
Biol Blood Marrow Transplant; 2011 May; 17(5):729-36. PubMed ID: 20813198
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization.
Yuan S; Nademanee A; Kaniewski M; Palmer J; Shayani S; Wang S
Transfusion; 2014 Aug; 54(8):2015-21. PubMed ID: 24660786
[TBL] [Abstract][Full Text] [Related]
7. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
8. Blood stem cell collection using chemotherapy with or without systematic G-CSF: experience in 52 patients with multiple myeloma.
Lefrere F; Makke J; Fermand J; Marolleau J; Dal Cortivo L; Alberti C; Mouton V; Benbunan M; Miclea J
Bone Marrow Transplant; 1999 Sep; 24(5):463-6. PubMed ID: 10482928
[TBL] [Abstract][Full Text] [Related]
9. A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
Mina R; Petrucci MT; Bonello F; Bongarzoni V; Saccardi R; Bertuglia G; Mengarelli A; Spadaro A; Lisi C; Curci P; Lemoli RM; Ballanti S; Floris R; Cupelli L; Tosi P; Olivieri A; Rota-Scalabrini D; Cangialosi C; Nozzoli C; Anaclerico B; Fazio F; Bruno B; Mancuso K; Corradini P; Milone G; Boccadoro M
Haematologica; 2024 May; 109(5):1525-1534. PubMed ID: 37981892
[TBL] [Abstract][Full Text] [Related]
10. Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant.
Veeraputhiran M; Jain T; Cronin S; Al-Kadhimi Z; Abidi MH; Ayash L; Mellert K; Lum LG; Ratanatharathorn V; Uberti JP; Deol A
J Clin Apher; 2014 Dec; 29(6):293-8. PubMed ID: 24700728
[TBL] [Abstract][Full Text] [Related]
11. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M
J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation.
Stover JT; Shaw JR; Kuchibhatla M; Horwitz ME; Engemann AM
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1290-1294. PubMed ID: 28411174
[TBL] [Abstract][Full Text] [Related]
13. [Effectiveness of plerixafor in patients undergoing mobilization autologous haematopoietic progenitor cell].
Ruano Camps R; Ortiz Pareja M; Vidales Mancha I; Muñoz Castillo IM; Heiniger Mazo AI
Farm Hosp; 2013; 37(4):317-21. PubMed ID: 24010693
[TBL] [Abstract][Full Text] [Related]
14. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.
Milone G; Martino M; Spadaro A; Leotta S; Di Marco A; Scalzulli P; Cupri A; Di Martina V; Schinocca E; Spina E; Tripepi G
Br J Haematol; 2014 Jan; 164(1):113-23. PubMed ID: 24138497
[TBL] [Abstract][Full Text] [Related]
15. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.
Awan F; Kochuparambil ST; Falconer DE; Cumpston A; Leadmon S; Watkins K; Deremer D; Jillella A; Craig M; Hamadani M
Bone Marrow Transplant; 2013 Oct; 48(10):1279-84. PubMed ID: 23584435
[TBL] [Abstract][Full Text] [Related]
16. Cost analysis of a randomized stem cell mobilization study in multiple myeloma.
Varmavuo V; Silvennoinen R; Anttila P; Säily M; Sankelo M; Putkonen M; Ahonen J; Mahlamäki E; Mäntymaa P; Savolainen ER; Remes K; Jantunen E
Ann Hematol; 2016 Oct; 95(10):1653-9. PubMed ID: 27485453
[TBL] [Abstract][Full Text] [Related]
17. Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series.
Lee SY; Sanchorawala V; Seldin DC; Mark Sloan J; Andrea N; Quillen K
Amyloid; 2014 Sep; 21(3):149-53. PubMed ID: 24779777
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.
Veltri L; Cumpston A; Shillingburg A; Wen S; Luo J; Leadmon S; Watkins K; Craig M; Hamadani M; Kanate AS
Cytotherapy; 2015 Dec; 17(12):1785-92. PubMed ID: 26475754
[TBL] [Abstract][Full Text] [Related]
20. A combination of low-dose cyclophosphamide and colony-stimulating factors is more cost-effective than granulocyte-colony-stimulating factors alone in mobilizing peripheral blood stem and progenitor cells.
Meisenberg B; Brehm T; Schmeckel A; Miller W; McMillan R
Transfusion; 1998 Feb; 38(2):209-15. PubMed ID: 9531956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]